Navigation Links
Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
Date:4/2/2013

ST. LOUIS, April 2, 2013 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that on April 1, 2013, it completed the purchase of Specialty Therapeutic Care Holdings, Inc. (d/b/a AcariaHealth), one of the nation's largest, independent, comprehensive specialty pharmacy companies, from Enhanced Equity Funds. The transaction was financed through a combination of approximately 1.7 million shares of Centene common stock, cash on hand as well as up to $15.3 million of Centene common stock from an equity offering related to funding the escrow account. 

Centene is working closely with AcariaHealth to ensure a seamless transition for customers and other key stakeholders.

The Company expects the acquisition to be neutral to earnings per share in the first 12 months following the acquisition, excluding one-time transaction costs. Additional details will be provided when Centene reports its first quarter financial results on April 23, 2013.

This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of any shares in any state in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such state.

About Centene Corporation

Centene Corporation, a Fortune 500 company, is a leading multi-line healthcare enterprise that provides programs and related services to the rising number of under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and long-term care, in addition to other state-sponsored programs, and Medicare (Special Needs Plans). Centene's CeltiCare subsidiary offers states unique, "exchange based"
'/>"/>

SOURCE Centene Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China Cord Blood Corporation Received AABB Accreditation
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. MGC Diagnostics Corporation Announces Special Cash Dividend and Extension of Stock Repurchase Program
4. Envent Corporation Opens Gulf Coast Headquarters in Texas
5. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
6. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
7. Neogen Corporation Announces 3rd Quarter Results Conference Call
8. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
11. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 30, 2015  With over 60,000 customers across the globe, ISN improves the efficiency ... organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide ... Headquartered in Dallas, TX , ISN ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... SCAI and Endovascular Forum Launch Interactive, Case-Based Website ... VEGAS, May 6 Whether it,s a common ... has likely seen a similar patient. That,s why ... and The Endovascular Forum, Inc. (EVF), an IC ...
... Fabre Dermatologie,specialised department of Pierre Fabre Laboratories, is ... clinical trials following the signature of an exclusive,and ... the University of,Bordeaux. The contract covers the development, ... treatment of severe infantile haemangioma,with the intention of ...
... Provides Simple, Reliable, Easy-to-Use and Affordable Automation for ... European Headquarters and Operations- -See CSampler at the ... American Society of Microbiology 109th Annual Meeting-ANN ARBOR, ... announced the commercial launch of CSampler(TM), an optional ...
Cached Biology Technology:New Website Connects Physicians to Solve Challenging Cases and Share Experiences 2New Website Connects Physicians to Solve Challenging Cases and Share Experiences 3New Website Connects Physicians to Solve Challenging Cases and Share Experiences 4Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma 2Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 2Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 3Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM) 4
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2008. A scientific project funded by the BBVA Foundation and ... Research (CSIC) explored around 100 kilometers of practically uncharted Atlantic ... between the years 2006 and 2007. In the course of ... new hope for the survival of the leatherback turtle. This ...
... an animal model of multiple sclerosis (MS), neuroradiologists and ... have been able to visualize inflammatory tissue damage, most ... the aid of a new contrast medium, Gadofluorine M, ... results in the online edition of the renowned medical ...
... the United States die every year from uncontrolled infections ... are pushing the boundaries of molecular science to find ... simple measure of an immune system protein within 24 ... shock can predict survival in children, yielding a powerful ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
...
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: